Use of phosphate-binding agents is associated with a lower risk of mortality
Jorge B. Cannata‐Andía(Universidad de Oviedo), Carmine Zoccali(Biogem), Draško Pavlović, José Emilio Hernández Sánchez(Hospital Universitario Ramón y Cajal), M Benedik(Ljubljana University Medical Centre), Aníbal Ferreira(Hospital Vila Franca de Xira), Gérard M. London(Unknown), Willem Jan W. Bos(St. Antonius Ziekenhuis), Dimitrios Memmos, Adrian Covic(Grigore T. Popa University of Medicine and Pharmacy), Markus Ketteler(Robert Bosch Hospital), José Luis Górriz(Universitat de València), David Goldsmith(University College London), Juan Jesús Carrero(Danderyds sjukhus), Manuel Naves‐Díaz(Universidad de Oviedo), Pablo Martínez‐Camblor(Dartmouth College), Vladimı́r Teplan(Institute of Clinical and Experimental Medicine), Francesco Locatelli(University of Modena and Reggio Emilia), Reinhard Kramar(Statistics Austria), Rudolf P. Wüthrich(University of Zurich), José Luis Fernández Martín(Universidad de Oviedo), Pierre‐Yves Martin(University Hospital of Geneva), Dierik Verbeelen(Vrije Universiteit Brussel), Jürgen Floege(RWTH Aachen University), Christian Tielemans(Vrije Universiteit Brussel), Judit Nagy(University of Pecs)
Cited by 158
Related Papers
Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2019|5.8k
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
|New England Journal of Medicine|2006|2.1k